However, after the cohort was stratified into APOEε4 carriers and non-carriers and the IgA levels were compared between NC and AD patients, the levels were significantly higher in AD patients compared to NC exclusively in APOEε4 non-carriers (Fig. 1C). This evidence concerns the gene CD79A and Alzheimer disease.